January 8, 2018 / 6:50 PM / Updated 21 minutes ago BRIEF-Sarepta Therapeutics Provides FY 2018 Rev Forecast For Exondys 51 Reuters Staff 1 Min Read 
Jan 8 (Reuters) - Sarepta Therapeutics Inc: 
* SAREPTA THERAPEUTICS PRE-ANNOUNCES FOURTH QUARTER 2017 REVENUE AND PROVIDES FULL-YEAR 2018 REVENUE GUIDANCE FOR EXONDYS 51® (ETEPLIRSEN), REPRESENTING APPROXIMATELY 100 PERCENT YEAR-OVER-YEAR GROWTH 
* Q4 REVENUE $57.3 MILLION VERSUS I/B/E/S VIEW $55.8 MILLION * SEES FY 2018 REVENUE $295 MILLION TO $305 MILLION 
* SAYS FULL-YEAR 2018 EXONDYS 51 REVENUE GUIDANCE OF $295 - $305 MILLION 
* SAYS ‍FULL-YEAR 2017 EXONDYS 51 UNAUDITED REVENUE OF $154.6 MILLION​ Source text for Eikon: Further company coverage: